このページの翻訳は実験的なもので、現在開発中です。お待ちしております

CombiGene マネジメント

マネジメント基準チェック /14

CombiGene'sの CEO はPeter Ekolindで、 Sep2023年に任命され、の在任期間は 1.08年です。の年間総報酬はSEK 893.49Kで、 80.6%給与と19.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.22%を直接所有しており、その価値はSEK 122.67K 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と1.5年です。

主要情報

Peter Ekolind

最高経営責任者

SEK 893.5k

報酬総額

CEO給与比率	80.6%
CEO在任期間	1.1yrs
CEOの所有権	0.2%
経営陣の平均在職期間	1.1yrs
取締役会の平均在任期間	1.5yrs

経営陣の近況

Recent updates

CEO報酬分析

CombiGene の収益と比較して、Peter Ekolind の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-SEK 37m
Mar 31 2024	n/a	n/a	-SEK 35m
Dec 31 2023	SEK 893k	SEK 720k	-SEK 36m

報酬と市場: Peterの総報酬 ($USD 85.62K ) は、 Swedish市場 ($USD 257.80K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Peterの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Peter Ekolind (60 yo)

1.1yrs

在職期間

SEK 893,492

報酬

Mr. Peter Ekolind served as Chief Operating Officer at CombiGene AB (publ) since September 27, 2022 and serves as its Chief Executive Officer since September 01, 2023. He serves as Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Peter Ekolind	Chief Executive Officer	1.1yrs	SEK 893.49k	0.22% SEK 111.3k
David Woldbye	Scientific Founder	no data	データなし	データなし
Merab Kokaia	Scientific Founder	no data	データなし	データなし
Louise Aspenberg	Chief Financial Officer	4.8yrs	データなし	データなし
Annika Ericson	Chief Scientific Officer	less than a year	データなし	データなし

1.1yrs

平均在職期間

60.5yo

平均年齢

経験豊富な経営陣: COMBIの経営陣は経験豊富とはみなされません ( 0.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Gunilla Lundmark	Independent Director	3.4yrs	SEK 125.00k	データなし
Jonas Ekblom	Independent Chairman of the Board	4.8yrs	SEK 150.03k	データなし
Marcus Isaksson	Director	less than a year	データなし	データなし
Andrew Rice	Member of Scientific Advisory Board	1.2yrs	データなし	データなし
Peter Nilsson	Independent Director	10.8yrs	SEK 163.90k	0.39% SEK 196.2k
Annamaria Vezzani	Member of Scientific Advisory Board	no data	データなし	データなし
Margitta Seeck	Member of Scientific Advisory Board	no data	データなし	データなし
Per Lundin	Independent Director	4.8yrs	SEK 62.50k	0.030% SEK 15.2k
Malin Almgren	Independent Director	1.8yrs	データなし	データなし
David Bennett	Member of Scientific Advisory Board	1.2yrs	データなし	データなし
Lars Arendt-Nielsen	Member of Scientific Advisory Board	1.2yrs	データなし	データなし
Sten Linnarsson	Member of the Scientific Advisory Board	less than a year	データなし	データなし

1.5yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: COMBIの取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

CombiGene マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Combigene AB (Publ) Appoints Annika Ericsson as New Chief Scientific Officer

CombiGene AB (publ) Approves Election of Marcus Isaksson as Board Member

CombiGene AB (publ), Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

CombiGene AB (publ) Announces Chief Executive Officer Changes

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released: kr0.38 loss per share (vs kr0.32 loss in 2Q 2023)

Combigene AB (Publ) Appoints Annika Ericsson as New Chief Scientific Officer

CombiGene AB (publ) Approves Election of Marcus Isaksson as Board Member

First quarter 2024 earnings released: kr0.72 loss per share (vs kr0.74 loss in 1Q 2023)

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Full year 2023 earnings released: kr1.80 loss per share (vs kr0.31 loss in FY 2022)

CombiGene AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)

CombiGene AB (publ), Annual General Meeting, May 23, 2024

New major risk - Share price stability

New major risk - Market cap size

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.23 profit in 2Q 2022)

CombiGene AB (publ) Announces Chief Executive Officer Changes

First quarter 2023 earnings released: kr0.74 loss per share (vs kr0.14 loss in 1Q 2022)

Full year 2022 earnings released: kr0.31 loss per share (vs kr1.21 profit in FY 2021)

CombiGene AB (publ) to Report Q1, 2023 Results on May 12, 2023

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

Investor sentiment improved over the past week

CombiGene Appoints Peter Ekolind as COO

Second quarter 2022 earnings released: EPS: kr0.23 (vs kr1.18 loss in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.95 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

CombiGene AB (publ), Annual General Meeting, May 19, 2022

CombiGene's (STO:COMBI) Earnings Are Weaker Than They Seem

Combigene AB (Publ) Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study

Is CombiGene (STO:COMBI) In A Good Position To Invest In Growth?

Board Member recently bought kr100k worth of stock

New 90-day low: kr0.51

CombiGene Announces the Material from the First Large-Scale Production of CG01 Now Released for Use in the Final Parts of the Preclinical Program

We Think CombiGene (STO:COMBI) Can Afford To Drive Business Growth

CEO & Director exercised options to buy kr82k worth of stock.

Third quarter 2020 earnings released: kr0.045 loss per share

New 90-day low: kr0.61

CombiGene Announces Update on Lipodystrophy Project CGT2

New 90-day low: kr0.64

New 90-day low: kr0.80

Earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14